BACKGROUND AND PURPOSE: Our aim was to describe an expanded experience with endovascular mechanical embolectomy in a broad group of patients, including those not meeting entry criteria for the MERCI multicenter trials. METHODS: We performed an analysis of all patients with ischemic stroke treated with the Merci Clot Retrieval Device at a single academic center outside of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trials. RESULTS: Twenty-four patients were treated with the device. Nine were MERCI trial ineligible: 4 received intravenous (IV) tissue plasminogen activator (tPA), 1 received IV tPA and was younger than 18 years of age, and 4 had time-to-treatment of longer than 8 hours. Mean age was 64 years (range, 14-89 years; 42% women). Median National Institutes of Health Stroke Scale (NIHSS) score was 21 (range, 11-30). Median symptoms-to-procedure-start time was 303 minutes (range, 85-2385 minutes). Recanalization (Thrombolysis in Myocardial Infarction, 2-3) was achieved in 15/24 (63%). In device-only patients, recanalization occurred in 10/16. In patients who failed IV tPA undergoing rescue embolectomy, recanalization was achieved in 4/5. Three patients unresponsive to device therapy received rescue intra-arterial tPA/abciximab; recanalization was achieved in 2/3. Recanalization was achieved in 3/4 patients in whom treatment was started longer than 8 hours after symptom onset. Asymptomatic hemorrhage occurred in 38%; symptomatic hemorrhage, in 8%. Three device fractures occurred; none worsened clinical outcome. In-hospital mortality was 17%; 90-day mortality, 29%. Good 90-day functional outcome (modified Rankin Scale, <or=2) was achieved by 25% (6/24). CONCLUSIONS: Endovascular mechanical embolectomy is an effective means of achieving revascularization in patients with acute ischemic stroke, including patients with late treatment start and intravenous tPA failure. Device-based therapy achieved recanalization in nearly two thirds of patients and good clinical outcomes in one fourth, with symptomatic hemorrhage in less than one tenth.
BACKGROUND AND PURPOSE: Our aim was to describe an expanded experience with endovascular mechanical embolectomy in a broad group of patients, including those not meeting entry criteria for the MERCI multicenter trials. METHODS: We performed an analysis of all patients with ischemic stroke treated with the Merci Clot Retrieval Device at a single academic center outside of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trials. RESULTS: Twenty-four patients were treated with the device. Nine were MERCI trial ineligible: 4 received intravenous (IV) tissue plasminogen activator (tPA), 1 received IV tPA and was younger than 18 years of age, and 4 had time-to-treatment of longer than 8 hours. Mean age was 64 years (range, 14-89 years; 42% women). Median National Institutes of Health Stroke Scale (NIHSS) score was 21 (range, 11-30). Median symptoms-to-procedure-start time was 303 minutes (range, 85-2385 minutes). Recanalization (Thrombolysis in Myocardial Infarction, 2-3) was achieved in 15/24 (63%). In device-only patients, recanalization occurred in 10/16. In patients who failed IV tPA undergoing rescue embolectomy, recanalization was achieved in 4/5. Three patients unresponsive to device therapy received rescue intra-arterial tPA/abciximab; recanalization was achieved in 2/3. Recanalization was achieved in 3/4 patients in whom treatment was started longer than 8 hours after symptom onset. Asymptomatic hemorrhage occurred in 38%; symptomatic hemorrhage, in 8%. Three device fractures occurred; none worsened clinical outcome. In-hospital mortality was 17%; 90-day mortality, 29%. Good 90-day functional outcome (modified Rankin Scale, <or=2) was achieved by 25% (6/24). CONCLUSIONS: Endovascular mechanical embolectomy is an effective means of achieving revascularization in patients with acute ischemic stroke, including patients with late treatment start and intravenous tPA failure. Device-based therapy achieved recanalization in nearly two thirds of patients and good clinical outcomes in one fourth, with symptomatic hemorrhage in less than one tenth.
Authors: J P Broderick; M Lu; R Kothari; S R Levine; P D Lyden; E C Haley; T G Brott; J Grotta; B C Tilley; J R Marler; M Frankel Journal: Stroke Date: 2000-10 Impact factor: 7.914
Authors: Richard P Felten; Neil R P Ogden; Carlos Peña; Miriam C Provost; Michael J Schlosser; Celia M Witten Journal: Stroke Date: 2004-12-29 Impact factor: 7.914
Authors: Wade S Smith; Gene Sung; Sidney Starkman; Jeffrey L Saver; Chelsea S Kidwell; Y Pierre Gobin; Helmi L Lutsep; Gary M Nesbit; Thomas Grobelny; Marilyn M Rymer; Isaac E Silverman; Randall T Higashida; Ronald F Budzik; Michael P Marks Journal: Stroke Date: 2005-06-16 Impact factor: 7.914
Authors: Y Pierre Gobin; Sidney Starkman; Gary R Duckwiler; Thomas Grobelny; Chelsea S Kidwell; Reza Jahan; John Pile-Spellman; Alan Segal; Fernando Vinuela; Jeffrey L Saver Journal: Stroke Date: 2004-10-28 Impact factor: 7.914
Authors: G Marchal; V Beaudouin; P Rioux; V de la Sayette; F Le Doze; F Viader; J M Derlon; J C Baron Journal: Stroke Date: 1996-04 Impact factor: 7.914
Authors: I Mourand; H Brunel; V Costalat; C Riquelme; K Lobotesis; D Milhaud; C Héroum; C Arquizan; M Moynier; A Bonafé Journal: AJNR Am J Neuroradiol Date: 2011-07-28 Impact factor: 3.825
Authors: Tobias Struffert; Martin Köhrmann; Tobias Engelhorn; Tim Nowe; Gregor Richter; Peter D Schellinger; Stefan Schwab; Arnd Doerfler Journal: Eur Radiol Date: 2009-04-07 Impact factor: 5.315
Authors: Lucas Restrepo; Oh Young Bang; Bruce Ovbiagele; Latisha Ali; Doojin Kim; David S Liebeskind; Sidney Starkman; Fernando Vinuela; Gary R Duckwiler; Reza Jahan; Jeffrey L Saver Journal: Cerebrovasc Dis Date: 2009-08-22 Impact factor: 2.762